Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Iyer

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2018
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation TherapyAlison K Yoder, Jillian R Gunther, Sarah A Milgrom, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Blood Advances|January 10, 2022
Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvementSerkan Akin, Chitra Hosing, Issa Khouri, et al.
JAMA Network Open|April 7, 2025
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T TherapyJames P Long, Rishab Prakash, Paul Edelkamp, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis BMan-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
Blood Advances|May 1, 2019
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphomaChelsea C Pinnix, Sarah A Milgrom, Chan Yoon Cheah, et al.
Blood Advances|August 19, 2025
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell LymphomaSwaminathan P Iyer, Neha Mehta-Shah, Ranjana H Advani, et al.
Leukemia & Lymphoma|January 22, 2021
The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapyAlexander Augustyn, L Jeffrey Medeiros, Ethan B Ludmir, et al.
Leukemia|September 20, 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapyPaolo Strati, Andrew P Jallouk, Ryan Sun, et al.
Oncotarget|January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2018
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation TherapyAlison K Yoder, Jillian R Gunther, Sarah A Milgrom, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Blood Advances|January 10, 2022
Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvementSerkan Akin, Chitra Hosing, Issa Khouri, et al.
JAMA Network Open|April 7, 2025
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T TherapyJames P Long, Rishab Prakash, Paul Edelkamp, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis BMan-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
Blood Advances|May 1, 2019
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphomaChelsea C Pinnix, Sarah A Milgrom, Chan Yoon Cheah, et al.
Blood Advances|August 19, 2025
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell LymphomaSwaminathan P Iyer, Neha Mehta-Shah, Ranjana H Advani, et al.
Leukemia & Lymphoma|January 22, 2021
The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapyAlexander Augustyn, L Jeffrey Medeiros, Ethan B Ludmir, et al.
Leukemia|September 20, 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapyPaolo Strati, Andrew P Jallouk, Ryan Sun, et al.
Oncotarget|January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Pageof 26